ESC 365 - Why is the baroreflex a relevant target for both resistant hypertension and heart failure?

ESC Premium Access

Why is the baroreflex a relevant target for both resistant hypertension and heart failure?

Session: Baroreflex activation therapy: its role in the management of heart failure and resistant hypertension

Topic: CHF - Non pharmacological treatment

Speaker: Professor A. Pathak (Monaco, MC)

Organised by Charité Medical School, supported with an educational grant by CVRx

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Atul Pathak

The Princess Grace Hospital Centre, Monaco (Monaco)

20 presentations

3 followers

3 more presentations in this session

Welcome and introduction - Baroreflex activation therapy: its role in the management of heart failure and resistant hypertension.

Speaker: Professor S. Anker (Berlin, DE) Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Resistant hypertension: stimulating the baroreflex when drugs have failed.

Speaker: Professor P. De Leeuw (Maastricht, NL)

Heart failure with reduced ejection fraction and a narrow QRS: how can baroreflex activation therapy help?

Speaker: Professor C. Butter (Bernau bei Berlin, DE)

Access the full session

Baroreflex activation therapy: its role in the management of heart failure and resistant hypertension

Speakers: Professor A. Pathak, Professor S. Anker, Professor F. Zannad, Professor P. De Leeuw, Professor C. Butter

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources